A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

SC0191

The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.

DRUG

SC0191 + Bevacizumab

"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."

DRUG

SC0191 + 5-FU/LV

"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."

Trial Locations (1)

200032

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Tianshu Liu

OTHER

NCT06363552 - A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter